Gilead Sciences (GILD) EBT Margin (2009 - 2026)
Gilead Sciences' (GILD) quarterly EBT Margin came in at 37.07% in Q1 2026, up 1234.0% YoY from 2.78% in Q1 2025, and up 41.37% on a QoQ basis from 26.22% in Q4 2025.
Gilead Sciences (GILD) EBT Margin (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of EBT Margin data on file, last reported at 37.07% in Q1 2026.
- Quarterly EBT Margin rose 1234.0% year-over-year to 37.07% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 36.08% (up 1233.0% YoY) and the FY2025 annual result came in at 33.27%, up 3087.0% from the prior year.
- EBT Margin climbed to 37.07% in Q1 2026, from 26.22% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 46.87% in Q3 2025 to a low of 67.1% in Q1 2024.
- A 5-year average of 21.02% and a median of 26.22% in 2025 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2024 — EBT Margin plunged 8756 bps — and 2025, when it surged 9183 bps.
- Tracing GILD's EBT Margin over 5 years: stood at 27.49% in 2022, then decreased by 15 bps to 23.24% in 2023, then advanced by 23 bps to 28.63% in 2024, then dropped by 8 bps to 26.22% in 2025, then surged by 41 bps to 37.07% in 2026.
- The last three EBT Margin figures came in at 37.07% (Q1 2026), 26.22% (Q4 2025), and 46.87% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 26.66% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 25.18% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -4.11% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 29.63% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 18.19% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 27.53% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -131.41% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -4.34% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 4.21% |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 127.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -131.41% |
| Mar 31, 2026 | 37.07% |
| Dec 31, 2025 | 26.22% |
| Sep 30, 2025 | 46.87% |
| Jun 30, 2025 | 34.30% |
| Mar 31, 2025 | 24.73% |
| Dec 31, 2024 | 28.63% |
| Sep 30, 2024 | 12.67% |
| Jun 30, 2024 | 29.52% |
| Mar 31, 2024 | -67.10% |
| Dec 31, 2023 | 23.24% |
| Sep 30, 2023 | 32.87% |
| Jun 30, 2023 | 24.06% |
| Mar 31, 2023 | 20.47% |
| Dec 31, 2022 | 27.49% |
| Sep 30, 2022 | 34.54% |
| Jun 30, 2022 | 24.01% |
| Mar 31, 2022 | -2.31% |
| Dec 31, 2021 | 10.48% |
| Sep 30, 2021 | 46.33% |